<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486859</url>
  </required_header>
  <id_info>
    <org_study_id>KY2020-794</org_study_id>
    <nct_id>NCT04486859</nct_id>
  </id_info>
  <brief_title>Postoperative Thrombosis Prevention in Patients With CD</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Cushing disease was randomized to 2 groups. After surgery, the patients were&#xD;
      managed with mechanical prevention or mechanical prevention plus anticoagulant drugs(LMWH&#xD;
      followed by rivaroxaban), VTE was observed 24h, 5day, 4weeks and 12weeks after&#xD;
      surgery.Bleeding events were also recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cushing disease, caused by ACTH-secreting pituitary adenomas, can lead to serious&#xD;
      complications with increased mortality. Minimally invasive surgery is currently the preferred&#xD;
      treatment for the disease, allowing more than 80% of tumors to be completely removed.&#xD;
      However, postoperative venous thrombosis (VTE), including deep vein thrombosis (DVT) and&#xD;
      pulmonary embolism (PE) pose great threats to patients' safety. According to the literatures&#xD;
      and the data from our center, up to 27% of the patients with Cushing's disease developed VTE&#xD;
      after surgery. Due to the lacking of a randomized prospective study, there is no consensus or&#xD;
      guideline on preventative anticoagulation protocols for postoperative management in patients&#xD;
      with Cushing's disease. This is a prospective randomized control study on preventative&#xD;
      anticoagulation in patients with Cushing's disease after transsphenoidal resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VTE incidence rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>DVT and PE incidence in 12 weeks after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DVT incidence rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>DVT in 12 weeks after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PE incidence rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>PE in 12 weeks after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 weeks</time_frame>
    <description>All-cause Mortality and VTE-specific Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic VTE incidence rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Symptomatic DVT and PE incidence in 12 weeks after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Cushing Disease</condition>
  <condition>DVT</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>mechanical prevention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients were managed with IPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mechanical plus anticoagulant drugs prevention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients were managed with IPC, and LMWH was added 24h after surgery and followed by rivaroxaban 5 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMWH/Rivaroxaban</intervention_name>
    <description>combined prevention</description>
    <arm_group_label>mechanical plus anticoagulant drugs prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IPC</intervention_name>
    <description>mechanical prevention</description>
    <arm_group_label>mechanical plus anticoagulant drugs prevention</arm_group_label>
    <arm_group_label>mechanical prevention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cushing's disease patient diagnosed and treated with transsphenoid surgery at study&#xD;
             centers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with thrombosis before surgery;&#xD;
&#xD;
          -  patients with cute bacterial endocarditis,&#xD;
&#xD;
          -  thrombocytopenia,&#xD;
&#xD;
          -  active peptic ulcer,&#xD;
&#xD;
          -  with contraindications to Rivaroxaban;&#xD;
&#xD;
          -  patients whose cranial MRA or CTA prompts abnormalities in intracranial blood vessels&#xD;
             which may be at risk of intracranial hemorrhage;&#xD;
&#xD;
          -  patients with coagulation abnormalities suggesting a high risk of bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Zhao</last_name>
      <phone>86-13916872553</phone>
      <email>zhaoyaohs@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Yao Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijuan Zhu</last_name>
      <phone>010-69156114</phone>
      <email>XXX@pumch.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoyun Zhang</investigator_full_name>
    <investigator_title>vice director of endocrine department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

